An external quality assessment (EQA) panel consisting of a total of 48 samples in bronchoalveolar lavage (BAL) fluid or transport medium was prepared in collaboration with Quality Control for Molecular Diagnostics (QCMD) (www.qcmd.org). The panel was used to assess the proficiency of the three laboratories that would be responsible for examining the 6,000 samples to be collected in the GRACE Network of Excellence (www.grace-lrti.org). The main objective was to decide on the best-performing testing approach for the detection of influenza viruses A and B, parainfluenza virus types 1 to 3, respiratory syncytial virus (RSV), human metapneumovirus, coronavirus, rhinovirus, adenovirus, Chlamydophila pneumoniae, Mycoplasma pneumoniae, and Legionella pneumophila by nucleic acid amplification techniques (NAATs). Two approaches were chosen: (i) laboratories testing samples using their in-house procedures for extraction and amplification and (ii) laboratories using their in-house amplification procedures on centrally extracted samples. Furthermore, three commercially available multiplex NAAT tests-the ResPlex (Qiagen GmbH, Hilden, Germany), RespiFinder plus (PathoFinder, Maastricht, The Netherlands), and RespiFinder Smart 21 (PathoFinder) tests-were evaluated by examination of the same EQA panel by the manufacturer. No large differences among the 3 laboratories were noticed when the performances of the assays developed in-house in combination with the inhouse extraction procedures were compared. Also, the extraction procedure (central versus local) had little effect on performance. However, large differences in amplification efficacy were found between the commercially available tests; acceptable results were obtained by using the PathoFinder assays.
G RACE (www.grace-lrti.org) is a Network of Excellence focusing on the complex and controversial field of communityacquired lower respiratory tract infections (CA-LRTI), which are among the leading reasons for seeking medical care. The promiscuous use of antibiotics for the treatment of CA-LRTI accounts for a major part of the community burden of antibiotic use and contributes dramatically to the rising prevalence of resistance among major human pathogens. The overall objective of GRACE is to combat antimicrobial resistance by integrating centers of research excellence and exploiting genomics in the investigation of CA-LRTI.
A multitude of nucleic acid amplification techniques (NAATs) for the detection of pathogenic organisms in respiratory specimens have been described (5, 8, 10) . Currently, a few commercial assays are available, but the majority of assays applied in clinical diagnostic laboratories have been developed in-house. Therefore, there is a need for interlaboratory exchange of clinical samples in order to compare results and evaluate individual assays, particularly when collaboration takes place in a multicenter network.
Part of the GRACE project is dedicated to the evaluation and validation of rapid diagnostic tests such as NAATs. One of the objectives is to select the best-performing strategy for nucleic acid (NA) extraction, amplification, and detection of pathogenic organisms involved in lower respiratory tract infections. The procedure selected will then be applied to specimens obtained from 3,000 adult patients presenting with lower respiratory tract infections at their general practitioners' offices and 3,000 matched controls.
In the present study, the complete coded external quality assessment (EQA) panel, consisting of 48 samples, was analyzed by PCR in two out of three diagnostic laboratories participating in the GRACE network. The third laboratory analyzed only the subpanel 3 samples. The three laboratories applied their own ''inhouse'' PCR protocols for extraction, amplification, and detection. Moreover, laboratory 3 also extracted the nucleic acids by using a NucliSens EasyMag extraction protocol, after which the extracted nucleic acids were sent to the other two laboratories for analysis with their in-house amplification and detection protocols. Thus, in total, two different DNA extraction methods, as well as different amplification and detection protocols, were evaluated. In addition, the GRACE EQA panel was also analyzed by three commercially available tests.
MATERIALS AND METHODS

Panel preparation and panel composition.
The EQA panel consisted of a total of 48 samples that had been included in previous Quality Control for Molecular Diagnostics (QCMD) EQA panels (2, 9, 11-14, 19, 20) and was Tables 4, 5 , and 6). The 21 samples in respiratory virus subpanel 1 contained a virus transport medium spiked with the following viruses in various concentrations: human metapneumovirus (hMPV) (n ϭ 4), influenza A virus (INF A) (n ϭ 5), influenza B virus (INF B) (n ϭ 1), respiratory syncytial virus (RSV) (n ϭ 3), parainfluenza virus type 1 (PIV-1) (n ϭ 3), PIV-2 (n ϭ 1), and PIV-3 (n ϭ 1). Three samples were negative for all viruses. The 13 samples in EQA subpanel 2, prepared in Dulbecco's modified Eagle's medium and fetal calf serum, were spiked with the following viruses in various concentrations: human coronaviruses (HCOV) (n ϭ 3), human rhinoviruses (HRV) (n ϭ 5), and human adenoviruses (HADV) (n ϭ 4). One sample was negative for all viruses. EQA subpanel 3 consisted of 14 samples spiked with the following bacteria in various concentrations: Mycoplasma pneumoniae (n ϭ 4), Chlamydophila pneumoniae (n ϭ 4), and Legionella pneumophila (n ϭ 4). Two samples were negative. The following EQA subpanel 3 samples were prepared in bronchoalveolar lavage (BAL) fluid: GRACE-37, GRACE-38, GRACE-39, GRACE-40, GRACE-44, GRACE-45, GRACE-47, and GRACE-48. All BAL fluid pools spiked with a respiratory virus or with M. pneumoniae, C. pneumoniae, or L. pneumophila were tested in triplicate by mono-PCRs for the presence of that specific organism but not for the presence of the other organisms, unless they were part of the same EQA panel.
Laboratories 1 and 2, as well as Qiagen GmbH (Hilden, Germany) and PathoFinder (Maastricht, The Netherlands), analyzed the complete panel. In laboratory 3, only samples from EQA subpanel 3 were analyzed.
Distribution of the proficiency panels. The panel samples were randomized by QCMD, freeze-dried, labeled, packed, and distributed at ambient temperature to participants along with a panel receipt form and an instruction manual. Results were reported back to QCMD.
External quality assessment process. The laboratories were given 5 weeks to test the panel samples using their routine molecular diagnostic tests and to return their results to QCMD. Participants were asked to return qualitative data (presence/absence) separately for each pathogen and, if available, (semi)quantitative data, e.g., cycle threshold (C T ) values.
RNA and DNA extractions. (i) RNA and DNA extractions at laboratory 1. Before the extraction of nucleic acid (NA), QCMD samples were reconstituted in 1 ml NA-free water and were spiked with internal controls-a known amount of phocine herpesvirus (DNA) and a known amount of encephalomyocarditis virus (RNA)-to monitor the efficient extraction of DNA and RNA, respectively, as described previously (4) . All 48 samples were tested separately for the pathogens. RNA and DNA extraction was performed by using a MagnaPure LC total nucleic acid kit (Roche Diagnostics, Mannheim, Germany) as described by Houben et al. (4) . Briefly, 200 l of a clinical specimen was mixed with lysis buffer and proteinase K and was subsequently incubated with magnetic particles to allow binding of the nucleic acid. Unbound material was removed by several washing steps. The nucleic acid was then eluted in 200 l of elution buffer and was directly used for cDNA synthesis (pathogens carrying an RNA genome) and real-time TaqMan PCR (RNA plus DNA pathogens).
(ii) RNA and DNA extractions at laboratory 2. The freeze-dried samples were resuspended in 1 ml of NA-free water. Subsequently, 200 l of this suspension was subjected to nucleic acid extraction using the MagNApure LC total nucleic acid kit, by following the same procedure as that used by laboratory 1. In laboratory 2, however, equine arteritis virus (EAV) was used as an internal control for RNA extractions.
(iii) RNA and DNA extractions at laboratory 3. Nucleic acids were extracted with the NucliSens EasyMag system (bioMérieux, Grenoble, France) as described previously (7). After extraction, three aliquots were prepared and were frozen at Ϫ70°C until frozen shipment to laboratories 1 and 2.
Amplification methods. (i) Amplification methods at laboratory 1. The isolated viral RNA was reverse transcribed using a MultiScribe reverse transcriptase (RT) kit and random hexamers (Applied Biosystems, Foster City, CA), according to the manufacturer's guidelines, followed by RT inactivation for 5 min at 95°C.
Primers and probes were selected using Primer Express software (Perkin-Elmer Applied Biosystems) and were based on highly conserved genomic regions. To cover subgroups, type-specific primers and probes were chosen for INF A and B, as well as for PIV-1 to -3. The forward and reverse primers, as well as the probes used, are given in Tables 1 through 3 .
Samples were assayed in duplicate in a 25-l reaction mixture containing 5 l of cDNA, 12.5 l of 2ϫ TaqMan universal PCR master mix (PerkinElmer Applied Biosystems), and the concentrations of the forward primers, reverse primers, and probes indicated in Table 1 . The fluorogenic probes were both labeled with the 5= reporter dye 6-carboxyfluorescein (FAM) and the 3= quencher dye 6-carboxytetramethylrhodamine (TAMRA). Amplification and detection were performed with an ABI Prism 7700 sequence detection system under the following conditions: 2 min of incubation at 50°C to attain optimal AmpErase uracil-N-glycosylase activity, 10 min at 95°C to activate the AmpliTaq Gold DNA polymerase, and 45 cycles of 15 s at 95°C and 1 min at 60°C. The viral load was determined by the number of amplification cycles needed for a positive PCR test (C T ). A C T value of 45 was chosen as a cutoff for sample positivity. Samples were controlled for the presence of possible inhibitors of the extraction or amplification reaction by the indicated internal controls: C T values had to range within clear-cut intervals. Positive results were confirmed by a second analysis of the same sample. In case of discrepant results, a third analysis was performed. C T values are mean values for duplicate reactions.
(ii) Amplification methods at laboratory 2. Primers and probes were designed using Beacon Designer software (Premier Biosoft International, Palo Alto, CA) and have been described previously (15, 16) , except that molecular beacons were replaced by TaqMan hydrolysis probes, using the same target sequences. The assays were performed as four multiplex realtime PCR assays, combining INF A, INF B, and RSV; PIV-1 to -4; HRV, hMPV, and the EAV internal control; and finally the four HCOV 229E, OC43, NL63, and HKU1. Real-time PCR was performed in 50 l of a reaction mixture consisting of 10 l of 5ϫ one-step RT-PCR buffer (One-Step RT-PCR kit; Qiagen, Hilden, Germany), 10 mM deoxynucleoside triphosphates (dNTPs), 4.5 mM MgCl 2 , 0.6 M each primer (Table 2) , and 0.34 M TaqMan probes, with 5 l of the template. The PCR thermal profile consisted of an initial cDNA step of 30 min at 50°C, followed by 15 min at 95°C and 45 cycles of 30 s at 95°C, 30 s at 55°C, and 30 s at 72°C.
For DNA targets, published assays (17) were used; these were performed in HotStar Taq master mix (Qiagen). Amplification, detection, and data analysis were performed using the iCycler IQ real-time detection system (Bio-Rad, Veenendaal, The Netherlands).
When samples were tested in duplicate reactions, one positive reaction was considered a positive result, since in proficiency testing, samples with concentrations around the limit of detection (LOD) can be detected. In case both reactions were positive, the value in the table is the mean value.
(iii) Amplification methods at laboratory 3. Real-time in-house mono-PCRs were applied as described previously for M. pneumoniae, C. pneumoniae, and L. pneumophila detection (6, 18) . Primers and probes are presented in Table 3 . Positive results were confirmed by a second analysis of the same sample. In case of discrepant results, a third analysis was performed.
Commercially available PCRs. The panels were sent to Qiagen GmbH to be analyzed by the ResPlex 1 assay and to PathoFinder to be analyzed by the RespiFinder plus and RespiFinder Smart 21 assays according to the manufacturer's instructions. After receiving the first ResPlex results, the manufacturer made modifications to the kit, producing the ResPlex 2 assay.
The RespiFinder Smart 21 assay is a real-time variant (under development) of the MultiFinder PCR technology (13) 
RESULTS
Results of in-house PCRs for the detection of respiratory viruses.
The performances of the NAATs for the detection of the respiratory viruses (subpanels 1 and 2) at laboratories 1 and 2 on extracts obtained with the routine MagNA pure LC and NucliSens EasyMag nucleic acid extraction procedures were comparable; no major differences in sensitivity and specificity were observed. Using its own protocol for extraction and amplification, laboratory 1 obtained one false-positive result (sample GRACE-02; PIV-2/4) and three false-negative results, all on samples with very low viral loads (samples GRACE-02, GRACE-08, and GRACE-33) ( Tables  4 and 5 ). When examining NucliSens EasyMag-extracted samples, laboratory 1 reported the correct virus in samples GRACE-09, GRACE-16, and GRACE-18, but each time in combination with PIV-2/4. Laboratory 2 reported two and three false-negative results after applying its own nucleic acid extraction procedure and the NucliSens EasyMag procedure, respectively, for the 21 samples of subpanel 1 and one and three false-negative results for the 13 samples of subpanel 2 (Tables 4 and 5 ). No false-positive results were reported after NucliSens EasyMag extraction, in contrast to four false-positive results obtained after laboratory 2 used its own nucleic acid extraction (Tables 4 and 5 ).
In general, after NucliSens EasyMag extraction, both laboratories obtained C T values equal to or lower than those obtained with their in-house extraction procedures (Tables 1 to 4) .
Results of in-house PCRs for the detection of atypical pathogens. In Table 6 , the results of the M. pneumoniae, C. pneumoniae, and L. pneumophila EQA subpanel are presented. No falsenegative results were reported by laboratories 1 and 3. Laboratory 2 failed to detect 3 positive samples: GRACE-38, containing the lowest concentration of M. pneumoniae, 50 color-changing units (CCU)/ml, and GRACE-45 and GRACE-47, spiked with 18 and 60 CFU/ml of L. pneumophila, respectively. None of the negativecontrol samples (negative transport medium [NTM]) were found positive by the three GRACE laboratories. In addition to the correct pathogens, laboratories 1 and 3 also detected M. pneumoniae in two samples. Laboratory 2 also found M. pneumoniae in one of these samples, indicating that contamination had occurred before the start of analysis of these samples. dium only, was reported to be positive for HRV by the ResPlex assay. GRACE-19 was spiked with RSV-A but was found to be positive for HRV by the ResPlex 1 assay and positive for HCOV and enterovirus by the ResPlex 2 assay. GRACE-16 was spiked with RSV-B but was found to be positive for INF B and HRV by the ResPlex 2 assay, whereas GRACE-12 contained INF A but was reported to be positive for HCOV and enterovirus by the same assay. Additionally, the ResPlex 2 assay identified 2 extra viruses in GRACE-03. Sample GRACE-21 was found to be positive for both HADV and RSV by all 4 commercial tests.
No difference in sensitivity was observed between the RespiFinder plus and the RespiFinder Smart 21 assay in examination of subpanel 2 for HADV, HCOV, and HRV (Tables 5 and 7) : both assays failed to detect HADV 31, HRV 16, and HRV 90 in samples GRACE-24, GRACE-25, and GRACE-33, respectively. The latter sample was also reported as negative by all of the in-house tests. The ResPlex assay (ResPlex 1) failed to detect the same three samples. Additionally, five other samples were also reported as negative by the ResPlex 1 assay. After modification of the assay to the ResPlex 2 format, sensitivity improved slightly, with five falsenegative results. No false-positive results were obtained with any of the commercially available assays.
Upon examination of subpanel 3, the RespiFinder plus assay failed to detect the sample spiked with 18 CFU of L. pneumophila (Table 6 ). All other samples were correctly identified. The RespiFinder Smart 21 assay did not detect any of the four samples spiked with L. pneumophila. The manufacturer was contacted on this issue and improved the assay. GRACE-37 and GRACE-39 were correctly identified as L. pneumophila-positive samples after retesting with a newer version of the RespiFinder Smart 21 assay. No other false-negative or false-positive results were reported by use of the RespiFinder assays.
The sensitivities of both ResPlex assays were very low. The original format (ResPlex 1) yielded only three positive samples, all with the highest loads of M. pneumoniae or C. pneumoniae. The assay failed to detect any L. pneumophila-positive samples. After the assay was adapted (ResPlex 2 results), no improvement was seen.
DISCUSSION
One of the objectives of this study was to check whether in-house nucleic acid extraction procedures could be replaced by a central nucleic acid extraction method with subsequent transport of extracts to other centers for nucleic acid amplification purposes in the context of a large study. The RNA and DNA sent to the participating laboratories were extracted from the EQA panel at laboratory 3 with the NucliSens EasyMag system, producing nucleic acid extracts of high quality, as reflected by the results obtained. After comparison of the results, the different extraction methods did not reveal significant differences: comparable sensitivities and specificities were obtained with both in-house nucleic acid extraction methods and the NucliSens EasyMag extraction procedure. Considering the overall workload and the results obtained, the method of choice for extraction of nucleic acids from respiratory samples collected in the GRACE network is the NucliSens EasyMag procedure performed in laboratory 3.
For comparison of the sensitivities and specificities of the different nucleic acid amplification methods, it was decided that laboratory 1 would apply its in-house PCRs for the detection of RSV, INF A/B, HCOV OC43, NL63, and 229E, and the polyomaviruses WUPyV and KIPyV. Laboratory 2 would examine samples for PIV-1 to -4, HRV, hMPV, HAdV, and bocavirus by using its inhouse PCRs, and the in-house PCRs of laboratory 3 would be used for the detection of M. pneumoniae, C. pneumoniae, and L. pneumophila. This decision was not based on C T values, since the BioRad iCycler, used in laboratory 2, usually gives higher C T values than the real-time equipment used in the other two laboratories.
The RespiFinder Smart 21 assay (PathoFinder) is a real-time multiplex PCR assay under development and is not yet commercially available. It is a further development of the MultiFinder technology as applied in the RespiFinder plus assay. According to the manufacturer (personal communication), the analytical sensitivity of the RespiFinder ranges from 5 to 50 copies per reaction for most targets when commercially available quantitated DNA/ RNA PCR controls (Vircell) are used. Seven samples positive for a respiratory virus were missed by the assay, two more than with the RespiFinder plus assay. All these samples contained low viral loads. All L. pneumophila-spiked samples were classified as negative based on the RespiFinder Smart 21 results, whereas two had been positive with the RespiFinder plus assay. The manufacturer was contacted on this issue and improved the assay. The commercially available ResPlex assay (Qiagen GmbH), a multiplex PCR, was also evaluated in this study but did not perform well. Even when the company had made some modifications to the kit after their first results (ResPlex 1), the performance of the assay improved only slightly (ResPlex 2), and it was considered too insensitive for further evaluations. The manufacturer was contacted and is aware of the sensitivity problems of the ResPlex assay. It intends to improve the sensitivity of the test. According to the literature, the analytical sensitivity reported by the supplier of the ResPlex II assay is about 500 viral genomes per reaction (21) . Serial dilutions of titrated strains were prepared by Wang et al., and sensitivities on the order of 3.0 · 10 Ϫ2 50% tissue culture infective dose (TCID 50 )/reaction for INF A, 1.0 · 10 Ϫ3 TCID 50 / reaction for INF B, 1.4 · 10 Ϫ1 TCID 50 /reaction for RSV, and 7.0 TCID 50 s/reaction for human enterovirus were found (21) . Lower sensitivities for the ResPlex II assay than for multiplex NAATs are also reported in the literature (1, 3) .
All samples used in this GRACE quality control (QC) panel originated from previous EQA distributions. All pools spiked with a respiratory virus or with M. pneumoniae, C. pneumoniae, or L. pneumophila were tested for the presence of that specific organism but not for the presence of the other organisms, unless they were part of the same EQA panel. When the commercially available multiplex assays were applied to the GRACE QC samples, more than 1 target organism was detected in some GRACE samples. If the result was confirmed by at least one of the other commercially available multiplex tests, e.g., GRACE-21 and GRACE-37, the additional organism was probably already present in the original pool, and the result should be considered correct. On the other hand, the detection of PIV-2/4 in GRACE-09, GRACE-16, and GRACE-18 (Table 4 ) and of HADV in GRACE-23, GRACE-28, and GRACE-31 (Table 5) was probably due to contamination that occurred during the extraction/amplification procedure. This conclusion is supported by the fact that the reported C T values are similar.
In conclusion, this study demonstrated the importance of including a sufficient number of weakly positive samples and negative controls in amplification runs to detect possible false-positive and false-negative results when the best-performing test must be selected and when a new assay is to be validated. 
